IN8bio (INAB) Registration filing summary

Company overview and business model

• Focuses on developing gamma-delta T cell therapies and engagers for cancer and autoimmune diseases, leveraging proprietary DeltEx platform technologies.

• Pipeline includes allogeneic, autologous, iPSC, and genetically modified cell therapy approaches, with clinical and preclinical programs targeting high-risk leukemias and glioblastoma.

• Mission centers on achieving 'Cancer Zero'—the safe elimination of all cancer cells in patients.

• Corporate history includes reincorporation in Delaware and a name change to IN8bio, Inc.

Financial performance and metrics

• Aggregate market value of common stock held by non-affiliates as of May 15, 2026, is $17,631,022, based on 8,815,511 shares at $2.00 per share.

• $4,959,074 of securities sold in the prior 12 months under Form S-3 limitations.

• Financial statements for 2025 and 2024 audited by CohnReznick LLP, with a going concern explanatory paragraph.

Use of proceeds and capital allocation

• Net proceeds from securities sales intended for working capital and general corporate purposes.

• Specific uses for proceeds from each offering will be detailed in the applicable prospectus supplement.